睡眠呼吸暂停治疗中CPAP设备聚氨酯泡沫降解的健康风险
该研究评估使用聚氨酯泡沫(PUF)降解的CPAP设备与不良健康结局的关联。PUF-CPAP患者尤其合并阻塞性肺疾病者抗阻塞药物使用增加,但住院和死亡率无差异,癌症数据不确定。
要点
- PUF-CPAP患者抗阻塞药物使用增加,尤其合并阻塞性肺疾病者。
- 住院和死亡率在PUF-CPAP与对照间无差异。
- 癌症数据不确定,需进一步研究。
核心结论
- PUF-CPAP使用与抗阻塞药物使用增加相关,尤其合并阻塞性肺疾病者,但住院和死亡率无差异,癌症数据不确定。
研究设计与样本
- 研究评估PUF-CPAP使用与OSA患者(伴/不伴OLD)不良健康结局的关联。
主要发现
- PUF-CPAP患者尤其合并OLD者抗阻塞药物使用增加。
- PUF-CPAP与对照间住院和死亡率无差异。
- 癌症数据不确定。
临床怎么用
- 对使用PUF-CPAP的OSA患者,尤其合并阻塞性肺疾病者,应关注抗阻塞药物使用增加。
局限性
- 癌症数据不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with PUF-CPAP and especially those with pre-existing obstructive lung disease had increased use of anti-obstructive medication but there were no differences in hospitalisations and mortality, and data on cancer were inconclusive https://bit.ly/3uVIzXG A recent medical device recall notification from Philips Respironics reported on risk for degradation of polyurethane foam (PUF) in continuous positive airway pressure (CPAP) devices used for obstructive sleep apnoea (OSA) treatment [1]. The degraded foam particles may cause airway irritation, and the volatile gas products (diethylene glycol, toluene di-isocyanate isomers, toluene diamine isomers) released during the degradation process may also have cyto- and genotoxic effects [1]. Kendzerska et al. [2] reported no increase in cancer incidence in 1220 patients using PUF devices over a mean observation time of 7.5 years. However, studies assessing airway symptoms and health outcomes other than cancer are lacking. Airway irritation from degraded foam particles may be particularly harmful for patients with pre-existing obstructive lung disease (OLD). This study aimed to evaluate the association between PUF-CPAP use and adverse health outcomes in OSA patients with/without comorbid OLD.
引用
- Palm A, Grote L, Ekström M, et al. Health risks related to polyurethane foam degradation in CPAP devices used for sleep apnoea treatment. Eur Respir J. 2022. PMID: 35144995. doi:10.1183/13993003.00237-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。